Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Did the FDA make the right call on propoxyphene?

This article was originally published in Scrip

Executive Summary

The decision by the US FDA at long last to pull propoxyphene-containing products from the US market (scripintelligence.com, 22 November 2010) has been greeted by the full gamut of responses, from those alleging it is part of a plot to force patients to use newer, more expensive medications to those who claim that the ruling is part of the Obama administration’s scheme to exert ever greater control over the individual.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC010920

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel